Search results
Results from the WOW.Com Content Network
The company's progress has not delivered strong returns in the past half-decade -- CRISPR Therapeutics has underperformed the market in this period. That said, there is a lot to like about the ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.. Incorporated in 1980 as AntiVirals, [2] shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta ...
The company owns and operates Asia's largest single-location animal biological manufacturing facility. [12] Hester Biosciences also has an R&D unit at Kadi, [ 10 ] and develops new animal vaccines, [ 7 ] an example of which is the Goat Pox vaccine Live-Uttarkashi strain used in India. [ 13 ]
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...